Alkermes plc ALKS
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +62.04%
- 1 year
- +47.11%
- Open
- 46.05
- Prev close
- 45.37
- Mkt cap
- 7.61B
- Vol
- 1.11M
- Avg vol
- 1.84M
- EPS
- 0.38
- P/E
- 119.32
- Div yield
- 0.00%
More statistics
- Low
- 44.78
- High
- 46.35
- Forward P/E
- 25.04
- Beta
- 0.27
- Short ratio
- 7.67
- Inst. own
- 107.80%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 44.11
- 200-d avg
- 40.40
- 1y target
- 56.21
6M chart
Events in this range
- May 5, 2026Earnings: -0.4; estimate -0.57; surprise 29.82%
- Jul 28, 2026Earnings: 0.7; estimate -0.02745; surprise 2650.09%
- Jul 28, 2026Rating: Piper Sandler · Overweight → Overweight
- Jul 29, 2026Rating: Baird · Outperform → Outperform
- Jul 29, 2026Rating: JP Morgan · Neutral → Neutral
- Sep 21, 2026Rating: Needham · Buy → Buy
- Sep 22, 2026Rating: Baird · Outperform → Outperform
- Sep 22, 2026Rating: RBC Capital · Outperform → Outperform
Signals (26)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 26, 2026 | 5 days ago |
| MACD: Buy Signal | Oct 5, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 18, 2026 | 1 month ago |
| RSI: Oversold | Sep 18, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| SMA: Bearish | Aug 18, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Aug 12, 2026 | 2 months ago |
| SMA: Bearish | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Aug 6, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 22, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 18, 2026 | 4 months ago |
| RSI: Overbought | Jun 18, 2026 | 4 months ago |
| RSI: Overbought | Jun 9, 2026 | 4 months ago |
| MACD: Buy Signal | May 28, 2026 | 5 months ago |
| RSI: Overbought | May 28, 2026 | 5 months ago |
| MACD: Sell Signal | May 21, 2026 | 5 months ago |
| RSI: Overbought | May 12, 2026 | 5 months ago |
| MACD: Buy Signal | May 5, 2026 | 5 months ago |
Key statistics
- Market cap
- 7.60B
- Enterprise value
- 8.53B
- Trailing P/E
- 119.17
- Forward P/E
- 25.04
- PEG ratio
- 1.96
- Price / sales
- 4.56
- Price / book
- 4.19
- EPS (TTM)
- 0.38
- Beta
- 0.27
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 3.96%
- Revenue (TTM)
- 1.67B
- Revenue growth
- 27.00%
- Free cash flow
- 153.38M
- Total cash
- 656.58M
- Total debt
- 1.57B
- Return on equity
- 3.85%
- Shares outstanding
- 167.76M
- Short % of float
- 15.73%
- 50-day average
- 44.11
- 200-day average
- 40.40
Analyst view
Consensus: buy
- Target (low)
- 38.00
- Target (mean)
- 56.21
- Target (high)
- 83.00
- Strong buy3
- Buy12
- Hold4
- Sell0
- Strong sell1
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate 0.24694.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -0.08155 | — | — | — |
| Jul 28, 2026 | Jun 30, 2026 | -0.02745 | 0.70 | +0.73 | +2,650.09% |
| May 5, 2026 | Mar 31, 2026 | -0.57 | -0.40 | +0.17 | +29.82% |
| Feb 25, 2026 | Dec 31, 2025 | 0.43 | 0.34 | -0.09 | -20.93% |
| Oct 28, 2025 | Sep 30, 2025 | 0.3688 | 0.49 | +0.12 | +32.86% |
| Jul 29, 2025 | Jun 30, 2025 | 0.41 | 0.52 | +0.11 | +26.83% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 22, 2026 | RBC Capital | reit | Outperform | Outperform |
| Sep 22, 2026 | Baird | main | Outperform | Outperform |
| Sep 21, 2026 | Needham | reit | Buy | Buy |
| Jul 29, 2026 | JP Morgan | main | Neutral | Neutral |
| Jul 29, 2026 | Baird | main | Outperform | Outperform |
| Jul 28, 2026 | Piper Sandler | reit | Overweight | Overweight |
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Ireland
- Website
- alkermes.com
News
- Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)
- Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Story
- Alkermes plc $ALKS Position Cut by Robeco Institutional Asset Management B.V.
- Alkermes to Report Third Quarter Financial Results on November 3, 2026
- Alkermes to Report Third Quarter Financial Results on November 3, 2026
- Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline
- Alkermes plc $ALKS Shares Sold by State of Alaska Department of Revenue
- Alkermes Plans To Present Two Oral Presentations And Six Posters From Portfolio Of Sleep Medicine Research At ESRS 28th Congress, Sleep Europe 2026
- Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
- 4 CNS Drug Stocks Worth Watching This World Mental Health Day
Your note
Sign in to keep a note on ALKS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BROWN IAIN MICHAEL | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 25, 2025 | 148,196 |
| COOKE SHANE M | Director | Conversion of Exercise of derivative security | May 20, 2026 | 106,679 |
| GAFFIN DAVID JOSEPH | Officer | Sale | Sep 2, 2026 | 223,422 |
| HOPKINSON CRAIG C | Officer | Conversion of Exercise of derivative security | Aug 31, 2026 | 65,389 |
| JACKSON BLAIR CURTIS | Chief Operating Officer | Conversion of Exercise of derivative security | Feb 25, 2026 | 241,308 |
| MCKEON BRIAN P | Director | Conversion of Exercise of derivative security | May 20, 2026 | 48,536 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 17.43% | 29,235,739 | 1.32B | Jun 29, 2026 |
| Baker Bros. Advisors, LP | 5.97% | 10,012,267 | 453.41M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.66% | 9,490,818 | 429.79M | Jun 29, 2026 |
| State Street Corporation | 5.46% | 9,160,575 | 414.84M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.48% | 7,515,025 | 340.32M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 4.02% | 6,737,328 | 305.10M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.96% | 9,993,409 | 452.55M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.16% | 5,297,487 | 239.90M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.59% | 4,340,866 | 196.58M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.28% | 3,823,805 | 173.16M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.94% | 3,254,864 | 147.40M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.31% | 2,202,262 | 99.73M | Jun 29, 2026 |